 | • レポートコード：MRC2-11QY08587 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は過活動膀胱（OAB）治療薬のグローバル市場について調査・分析したレポートです。種類別（抗コリン作用薬、ベータ-3アドレナリン受容体作動薬）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別過活動膀胱（OAB）治療薬の競争状況、市場シェア ・世界の過活動膀胱（OAB）治療薬市場：種類別市場規模 2015年-2020年（抗コリン作用薬、ベータ-3アドレナリン受容体作動薬） ・世界の過活動膀胱（OAB）治療薬市場：種類別市場規模予測 2021年-2026年（抗コリン作用薬、ベータ-3アドレナリン受容体作動薬） ・世界の過活動膀胱（OAB）治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の過活動膀胱（OAB）治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の過活動膀胱（OAB）治療薬市場分析：米国、カナダ ・ヨーロッパの過活動膀胱（OAB）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの過活動膀胱（OAB）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の過活動膀胱（OAB）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの過活動膀胱（OAB）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Allergan、Astellas Pharma、Hisamitsu Pharmaceutical、Pfizer、Ferring、GlaxoSmithKline、Ion Channel Innovations、Kwang Dong Pharmaceutical、Lanzhou Institute of Biological Products、Merck、ONO Pharmaceutical、Sanofi、Tengion、Teva Pharmaceutical Industries ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
Market Analysis and Insights: Global Overactive Bladder (OAB) Therapeutics Market
The global Overactive Bladder (OAB) Therapeutics market size is projected to reach US$ 3251.3 million by 2026, from US$ 3194.5 million in 2020, at a CAGR of 1.6%% during 2021-2026.
Global Overactive Bladder (OAB) Therapeutics Scope and Market Size
Overactive Bladder (OAB) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Overactive Bladder (OAB) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Overactive Bladder (OAB) Therapeutics market is segmented into
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application, the Overactive Bladder (OAB) Therapeutics market is segmented into
Hosptial
Clinci
Other
Regional and Country-level Analysis
The Overactive Bladder (OAB) Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Overactive Bladder (OAB) Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Overactive Bladder (OAB) Therapeutics Market Share Analysis
Overactive Bladder (OAB) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Overactive Bladder (OAB) Therapeutics business, the date to enter into the Overactive Bladder (OAB) Therapeutics market, Overactive Bladder (OAB) Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
1 Study Coverage
1.1 Overactive Bladder (OAB) Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Overactive Bladder (OAB) Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type
1.4.2 Anticholinergic Agents
1.4.3 Beta-3 Adrenoreceptor Agonists
1.5 Market by Application
1.5.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application
1.5.2 Hosptial
1.5.3 Clinci
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Overactive Bladder (OAB) Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2015-2026
2.1.2 Global Overactive Bladder (OAB) Therapeutics Sales 2015-2026
2.2 Global Overactive Bladder (OAB) Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Overactive Bladder (OAB) Therapeutics Competitor Landscape by Players
3.1 Overactive Bladder (OAB) Therapeutics Sales by Manufacturers
3.1.1 Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers
3.2.1 Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Overactive Bladder (OAB) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Overactive Bladder (OAB) Therapeutics Revenue in 2019
3.2.5 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Overactive Bladder (OAB) Therapeutics Price by Manufacturers
3.4 Overactive Bladder (OAB) Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Overactive Bladder (OAB) Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020)
4.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2015-2020)
4.1.3 Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020)
5.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2015-2020)
5.1.3 Overactive Bladder (OAB) Therapeutics Price by Application (2015-2020)
5.2 Overactive Bladder (OAB) Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Overactive Bladder (OAB) Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Overactive Bladder (OAB) Therapeutics by Country
6.1.1 North America Overactive Bladder (OAB) Therapeutics Sales by Country
6.1.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Type
6.3 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Overactive Bladder (OAB) Therapeutics by Country
7.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Country
7.1.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Type
7.3 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Overactive Bladder (OAB) Therapeutics by Region
8.1.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region
8.1.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Overactive Bladder (OAB) Therapeutics by Country
9.1.1 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country
9.1.2 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Type
9.3 Central & South America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Country
10.1.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country
10.1.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Allergan
11.1.1 Allergan Corporation Information
11.1.2 Allergan Description and Business Overview
11.1.3 Allergan Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered
11.1.5 Allergan Related Developments
11.2 Astellas Pharma
11.2.1 Astellas Pharma Corporation Information
11.2.2 Astellas Pharma Description and Business Overview
11.2.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Products Offered
11.2.5 Astellas Pharma Related Developments
11.3 Hisamitsu Pharmaceutical
11.3.1 Hisamitsu Pharmaceutical Corporation Information
11.3.2 Hisamitsu Pharmaceutical Description and Business Overview
11.3.3 Hisamitsu Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
11.3.5 Hisamitsu Pharmaceutical Related Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Description and Business Overview
11.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered
11.4.5 Pfizer Related Developments
11.5 Ferring
11.5.1 Ferring Corporation Information
11.5.2 Ferring Description and Business Overview
11.5.3 Ferring Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered
11.5.5 Ferring Related Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Description and Business Overview
11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered
11.6.5 GlaxoSmithKline Related Developments
11.7 Ion Channel Innovations
11.7.1 Ion Channel Innovations Corporation Information
11.7.2 Ion Channel Innovations Description and Business Overview
11.7.3 Ion Channel Innovations Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered
11.7.5 Ion Channel Innovations Related Developments
11.8 Kwang Dong Pharmaceutical
11.8.1 Kwang Dong Pharmaceutical Corporation Information
11.8.2 Kwang Dong Pharmaceutical Description and Business Overview
11.8.3 Kwang Dong Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
11.8.5 Kwang Dong Pharmaceutical Related Developments
11.9 Lanzhou Institute of Biological Products
11.9.1 Lanzhou Institute of Biological Products Corporation Information
11.9.2 Lanzhou Institute of Biological Products Description and Business Overview
11.9.3 Lanzhou Institute of Biological Products Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered
11.9.5 Lanzhou Institute of Biological Products Related Developments
11.10 Merck
11.10.1 Merck Corporation Information
11.10.2 Merck Description and Business Overview
11.10.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Merck Overactive Bladder (OAB) Therapeutics Products Offered
11.10.5 Merck Related Developments
11.1 Allergan
11.1.1 Allergan Corporation Information
11.1.2 Allergan Description and Business Overview
11.1.3 Allergan Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered
11.1.5 Allergan Related Developments
11.12 Sanofi
11.12.1 Sanofi Corporation Information
11.12.2 Sanofi Description and Business Overview
11.12.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Sanofi Products Offered
11.12.5 Sanofi Related Developments
11.13 Tengion
11.13.1 Tengion Corporation Information
11.13.2 Tengion Description and Business Overview
11.13.3 Tengion Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Tengion Products Offered
11.13.5 Tengion Related Developments
11.14 Teva Pharmaceutical Industries
11.14.1 Teva Pharmaceutical Industries Corporation Information
11.14.2 Teva Pharmaceutical Industries Description and Business Overview
11.14.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Teva Pharmaceutical Industries Products Offered
11.14.5 Teva Pharmaceutical Industries Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Overactive Bladder (OAB) Therapeutics Market Estimates and Projections by Region
12.1.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Overactive Bladder (OAB) Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Overactive Bladder (OAB) Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Overactive Bladder (OAB) Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Overactive Bladder (OAB) Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Overactive Bladder (OAB) Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Overactive Bladder (OAB) Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Overactive Bladder (OAB) Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Overactive Bladder (OAB) Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Overactive Bladder (OAB) Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Overactive Bladder (OAB) Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Overactive Bladder (OAB) Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Overactive Bladder (OAB) Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Overactive Bladder (OAB) Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Overactive Bladder (OAB) Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Overactive Bladder (OAB) Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Overactive Bladder (OAB) Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Overactive Bladder (OAB) Therapeutics Market Segments
Table 2. Ranking of Global Top Overactive Bladder (OAB) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million)
Table 4. Major Manufacturers of Anticholinergic Agents
Table 5. Major Manufacturers of Beta-3 Adrenoreceptor Agonists
Table 6. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application 2020-2026 (MT)
Table 7. Global Overactive Bladder (OAB) Therapeutics Market Size by Region (MT) & (US$ Million): 2020 VS 2026
Table 8. Global Overactive Bladder (OAB) Therapeutics Sales by Regions 2015-2020 (MT)
Table 9. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Regions (2015-2020)
Table 10. Global Overactive Bladder (OAB) Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2015-2020) (MT)
Table 12. Global Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers (2015-2020)
Table 13. Global Overactive Bladder (OAB) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Overactive Bladder (OAB) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2019)
Table 15. Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Overactive Bladder (OAB) Therapeutics Price (2015-2020) (USD/Kg)
Table 18. Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Overactive Bladder (OAB) Therapeutics Product Type
Table 20. Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT)
Table 23. Global Overactive Bladder (OAB) Therapeutics Sales Share by Type (2015-2020)
Table 24. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2015-2020)
Table 26. Overactive Bladder (OAB) Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Kg)
Table 27. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT)
Table 28. Global Overactive Bladder (OAB) Therapeutics Sales Share by Application (2015-2020)
Table 29. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT)
Table 30. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020)
Table 31. North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020)
Table 33. North America Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT)
Table 34. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020)
Table 35. North America Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT)
Table 36. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020)
Table 37. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT)
Table 38. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020)
Table 39. Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020)
Table 41. Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT)
Table 42. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020)
Table 43. Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT)
Table 44. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2015-2020) (MT)
Table 46. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT)
Table 50. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT)
Table 52. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020)
Table 53. Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT)
Table 54. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020)
Table 57. Latin America Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT)
Table 58. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020)
Table 59. Latin America Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT)
Table 60. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2015-2020) (MT)
Table 62. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Type (2015-2020) (MT)
Table 66. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Application (2015-2020) (MT)
Table 68. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020)
Table 69. Allergan Corporation Information
Table 70. Allergan Description and Major Businesses
Table 71. Allergan Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 72. Allergan Product
Table 73. Allergan Recent Development
Table 74. Astellas Pharma Corporation Information
Table 75. Astellas Pharma Description and Major Businesses
Table 76. Astellas Pharma Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 77. Astellas Pharma Product
Table 78. Astellas Pharma Recent Development
Table 79. Hisamitsu Pharmaceutical Corporation Information
Table 80. Hisamitsu Pharmaceutical Description and Major Businesses
Table 81. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 82. Hisamitsu Pharmaceutical Product
Table 83. Hisamitsu Pharmaceutical Recent Development
Table 84. Pfizer Corporation Information
Table 85. Pfizer Description and Major Businesses
Table 86. Pfizer Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 87. Pfizer Product
Table 88. Pfizer Recent Development
Table 89. Ferring Corporation Information
Table 90. Ferring Description and Major Businesses
Table 91. Ferring Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 92. Ferring Product
Table 93. Ferring Recent Development
Table 94. GlaxoSmithKline Corporation Information
Table 95. GlaxoSmithKline Description and Major Businesses
Table 96. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 97. GlaxoSmithKline Product
Table 98. GlaxoSmithKline Recent Development
Table 99. Ion Channel Innovations Corporation Information
Table 100. Ion Channel Innovations Description and Major Businesses
Table 101. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 102. Ion Channel Innovations Product
Table 103. Ion Channel Innovations Recent Development
Table 104. Kwang Dong Pharmaceutical Corporation Information
Table 105. Kwang Dong Pharmaceutical Description and Major Businesses
Table 106. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 107. Kwang Dong Pharmaceutical Product
Table 108. Kwang Dong Pharmaceutical Recent Development
Table 109. Lanzhou Institute of Biological Products Corporation Information
Table 110. Lanzhou Institute of Biological Products Description and Major Businesses
Table 111. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 112. Lanzhou Institute of Biological Products Product
Table 113. Lanzhou Institute of Biological Products Recent Development
Table 114. Merck Corporation Information
Table 115. Merck Description and Major Businesses
Table 116. Merck Overactive Bladder (OAB) Therapeutics Production (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 117. Merck Product
Table 118. Merck Recent Development
Table 119. ONO Pharmaceutical Corporation Information
Table 120. ONO Pharmaceutical Description and Major Businesses
Table 121. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 122. ONO Pharmaceutical Product
Table 123. ONO Pharmaceutical Recent Development
Table 124. Sanofi Corporation Information
Table 125. Sanofi Description and Major Businesses
Table 126. Sanofi Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 127. Sanofi Product
Table 128. Sanofi Recent Development
Table 129. Tengion Corporation Information
Table 130. Tengion Description and Major Businesses
Table 131. Tengion Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 132. Tengion Product
Table 133. Tengion Recent Development
Table 134. Teva Pharmaceutical Industries Corporation Information
Table 135. Teva Pharmaceutical Industries Description and Major Businesses
Table 136. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 137. Teva Pharmaceutical Industries Product
Table 138. Teva Pharmaceutical Industries Recent Development
Table 139. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Regions (2021-2026) (MT)
Table 140. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 141. Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 142. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 143. North America: Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2021-2026) (MT)
Table 144. North America: Overactive Bladder (OAB) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 145. Europe: Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2021-2026) (MT)
Table 146. Europe: Overactive Bladder (OAB) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 147. Asia Pacific: Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2021-2026) (MT)
Table 148. Asia Pacific: Overactive Bladder (OAB) Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 149. Latin America: Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2021-2026) (MT)
Table 150. Latin America: Overactive Bladder (OAB) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 151. Middle East and Africa: Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2021-2026) (MT)
Table 152. Middle East and Africa: Overactive Bladder (OAB) Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 153. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 154. Key Challenges
Table 155. Market Risks
Table 156. Main Points Interviewed from Key Overactive Bladder (OAB) Therapeutics Players
Table 157. Overactive Bladder (OAB) Therapeutics Customers List
Table 158. Overactive Bladder (OAB) Therapeutics Distributors List
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Overactive Bladder (OAB) Therapeutics Product Picture
Figure 2. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Anticholinergic Agents Product Picture
Figure 4. Beta-3 Adrenoreceptor Agonists Product Picture
Figure 5. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 6. Hosptial
Figure 7. Clinci
Figure 8. Other
Figure 9. Overactive Bladder (OAB) Therapeutics Report Years Considered
Figure 10. Global Overactive Bladder (OAB) Therapeutics Market Size 2015-2026 (US$ Million)
Figure 11. Global Overactive Bladder (OAB) Therapeutics Sales 2015-2026 (MT)
Figure 12. Global Overactive Bladder (OAB) Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2015-2020)
Figure 14. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2019
Figure 15. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2015-2020)
Figure 16. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in 2019
Figure 17. Global Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturer in 2019
Figure 18. The Top 10 and 5 Players Market Share by Overactive Bladder (OAB) Therapeutics Revenue in 2019
Figure 19. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2015-2020)
Figure 21. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type in 2019
Figure 22. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2015-2020)
Figure 23. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type in 2019
Figure 24. Global Overactive Bladder (OAB) Therapeutics Market Share by Price Range (2015-2020)
Figure 25. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2015-2020)
Figure 26. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application in 2019
Figure 27. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2015-2020)
Figure 28. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application in 2019
Figure 29. North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT)
Figure 30. North America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 31. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019
Figure 32. North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019
Figure 33. U.S. Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 34. U.S. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Canada Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 36. Canada Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. North America Overactive Bladder (OAB) Therapeutics Market Share by Type in 2019
Figure 38. North America Overactive Bladder (OAB) Therapeutics Market Share by Application in 2019
Figure 39. Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT)
Figure 40. Europe Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019
Figure 42. Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019
Figure 43. Germany Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 44. Germany Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. France Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 46. France Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. U.K. Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 48. U.K. Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Italy Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 50. Italy Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Russia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 52. Russia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Europe Overactive Bladder (OAB) Therapeutics Market Share by Type in 2019
Figure 54. Europe Overactive Bladder (OAB) Therapeutics Market Share by Application in 2019
Figure 55. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT)
Figure 56. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 57. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2019
Figure 58. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region in 2019
Figure 59. China Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 60. China Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Japan Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 62. Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. South Korea Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 64. South Korea Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. India Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 66. India Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Australia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 68. Australia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Taiwan Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 70. Taiwan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Indonesia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 72. Indonesia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Thailand Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 74. Thailand Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Malaysia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 76. Malaysia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Philippines Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 78. Philippines Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Vietnam Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 80. Vietnam Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Asia Pacific Overactive Bladder (OAB) Therapeutics Market Share by Type in 2019
Figure 82. Asia Pacific Overactive Bladder (OAB) Therapeutics Market Share by Application in 2019
Figure 83. Latin America Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT)
Figure 84. Latin America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 85. Latin America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019
Figure 86. Latin America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019
Figure 87. Mexico Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 88. Mexico Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Brazil Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 90. Brazil Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Argentina Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 92. Argentina Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Latin America Overactive Bladder (OAB) Therapeutics Market Share by Type in 2019
Figure 94. Latin America Overactive Bladder (OAB) Therapeutics Market Share by Application in 2019
Figure 95. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2015-2020 (MT)
Figure 96. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2019
Figure 98. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Country in 2019
Figure 99. Turkey Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 100. Turkey Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 102. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. U.A.E Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2015-2020) (MT)
Figure 104. U.A.E Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share by Type in 2019
Figure 106. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share by Application in 2019
Figure 107. North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate Forecast (2021-2026) (MT)
Figure 108. North America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 109. Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate Forecast (2021-2026) (MT)
Figure 110. Europe Overactive Bladder (OAB) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate Forecast (2021-2026) (MT)
Figure 112. Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Latin America Overactive Bladder (OAB) Therapeutics Sales Growth Rate Forecast (2021-2026) (MT)
Figure 114. Latin America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate Forecast (2021-2026) (MT)
Figure 116. Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Porter's Five Forces Analysis
Figure 118. Channels of Distribution
Figure 119. Distributors Profiles
Figure 120. Bottom-up and Top-down Approaches for This Report
Figure 121. Data Triangulation
Figure 122. Key Executives Interviewed
過活動膀胱治療薬の世界市場（～2026年） Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). North America is the largest consumption market of Overactive …- 膀胱がん治療・診断の世界市場（～2026年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…
- 膀胱がん治療薬の世界市場（～2026年） Bladder cancer refers to the growth of abnormal tissues in the lining of the bladder. These abnormal tissues are referred to as tumor, which even spread in the surrounding tissues or muscles. The increase in prevalence of bladder cancer, advanced health care services, technological advancements, dr…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- 肥大型心筋症治療薬の世界市場（～2026年） HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers …